Background: Basal cell carcinoma (BCC) is the most common cancer in humans. Medical treatment modalities offer cost reductions and clinical advantages in selected cases such as low-risk areas, surgically inaccessible sites, patients with multiple neoplasms, and older, infirm or anticoagulated subjects. Tazarotene has been proposed for the treatment of BCC; however, data on its efficacy are lacking. Objectives: To investigate the efficacy of tazarotene in a large series of BCCs, better to define the clinical advantages and the mechanisms of action in vivo. Methods: Tazarotene 0.1% gel was applied daily for 24 weeks to 154 small superficial and nodular BBCs. Clinicopathological changes were followed during the therapy by dermoscopic and histo-logical examination. Proliferation, retinoic acid receptors and apoptosis were investigated by immunohistochemistry and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphos-phate-biotin nick-end labelling on biopsies. Results: At 24 weeks of therapy, 70.8% of the BCCs showed > 50% clinical and dermoscopic regression, and 30.5% healed without recurrences after 3 years of follow-up. At 12 weeks, biopsies showed that regression was associated with reduced proliferation and increased apoptosis of basaliomatous cells. Most unresponsive tumours displayed a keratotic differentiation. Conclusions: Tazarotene was effective in the majority of superficial and nodular undifferentiated BCCs treated, possibly by antiproliferative and proapoptotic actions in vivo. Keratotic BCCs were the major type among the unresponsive tumours, and were characterized by overexpression of p53 and cellular retinol binding protein-1 in comparison with undifferentiated tumours. Topical tazarotene represents an alternative medical choice for selected cases of BCC.

Bianchi, L., Orlandi, A., Campione, E., Angeloni, C., Costanzo, A., Spagnoli, L.G., et al. (2004). Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. BRITISH JOURNAL OF DERMATOLOGY, 151(1), 148-156 [10.1111/j.1365-2133.2004.06044.x].

Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases

BIANCHI, LUCA;ORLANDI, AUGUSTO;Campione, E;COSTANZO, ANTONIO;SPAGNOLI, LUIGI GIUSTO;CHIMENTI, SERGIO
2004

Abstract

Background: Basal cell carcinoma (BCC) is the most common cancer in humans. Medical treatment modalities offer cost reductions and clinical advantages in selected cases such as low-risk areas, surgically inaccessible sites, patients with multiple neoplasms, and older, infirm or anticoagulated subjects. Tazarotene has been proposed for the treatment of BCC; however, data on its efficacy are lacking. Objectives: To investigate the efficacy of tazarotene in a large series of BCCs, better to define the clinical advantages and the mechanisms of action in vivo. Methods: Tazarotene 0.1% gel was applied daily for 24 weeks to 154 small superficial and nodular BBCs. Clinicopathological changes were followed during the therapy by dermoscopic and histo-logical examination. Proliferation, retinoic acid receptors and apoptosis were investigated by immunohistochemistry and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphos-phate-biotin nick-end labelling on biopsies. Results: At 24 weeks of therapy, 70.8% of the BCCs showed > 50% clinical and dermoscopic regression, and 30.5% healed without recurrences after 3 years of follow-up. At 12 weeks, biopsies showed that regression was associated with reduced proliferation and increased apoptosis of basaliomatous cells. Most unresponsive tumours displayed a keratotic differentiation. Conclusions: Tazarotene was effective in the majority of superficial and nodular undifferentiated BCCs treated, possibly by antiproliferative and proapoptotic actions in vivo. Keratotic BCCs were the major type among the unresponsive tumours, and were characterized by overexpression of p53 and cellular retinol binding protein-1 in comparison with undifferentiated tumours. Topical tazarotene represents an alternative medical choice for selected cases of BCC.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - Malattie Cutanee e Veneree
English
Con Impact Factor ISI
apoptosis; basal cell carcinoma; proliferation; retinoic acid receptors; tazarotene; therapy
retinoic acid receptor; tazarotene; adult; aged; apoptosis; article; basal cell carcinoma; cancer recurrence; cancer regression; cell proliferation; controlled study; drug efficacy; drug mechanism; female; follow up; histopathology; human; human tissue; immunohistochemistry; major clinical study; male; priority journal; treatment outcome; administration, topical; adult; aged; aged, 80 and over; antineoplastic agents; bcl-2-associated X protein; carcinoma, basal cell; cell division; female; follow-up studies; humans; immunohistochemistry; in situ nick-end labeling; male; middle aged; nicotinic acids; proto-oncogene proteins; proto-oncogene proteins c-bcl-2; receptors, retinoic acid; retinol-binding proteins; skin neoplasms; statistics, nonparametric; treatment outcome
Bianchi, L., Orlandi, A., Campione, E., Angeloni, C., Costanzo, A., Spagnoli, L.G., et al. (2004). Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. BRITISH JOURNAL OF DERMATOLOGY, 151(1), 148-156 [10.1111/j.1365-2133.2004.06044.x].
Bianchi, L; Orlandi, A; Campione, E; Angeloni, C; Costanzo, A; Spagnoli, Lg; Chimenti, S
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Topical treatment of basal cell carcinoma with tazarotene .. BRITISH JOURNAL OF DERMATOLOGY, 2004, 151, 148-156.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 448.17 kB
Formato Adobe PDF
448.17 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/56988
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 48
social impact